NexImmune (NEXI)
(Delayed Data from OTC)
$0.25 USD
-0.05 (-16.67%)
Updated Sep 20, 2024 02:55 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for NexImmune, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 33 | 63 | 53 | 28 | 21 |
Income After Depreciation & Amortization | -33 | -63 | -53 | -28 | -21 |
Non-Operating Income | 1 | 1 | 3 | 0 | 0 |
Interest Expense | 0 | 0 | 1 | 2 | 0 |
Pretax Income | -32 | -63 | -51 | -30 | -21 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -32 | -63 | -51 | -30 | -21 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -32 | -63 | -51 | -30 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -32 | -62 | -52 | -27 | -20 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -33 | -63 | -53 | -28 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.05 | 0.96 | 0.81 | 0.05 | NA |
Diluted EPS Before Non-Recurring Items | -30.82 | -65.00 | -63.50 | -660.50 | NA |
Diluted Net EPS (GAAP) | -30.82 | -65.00 | -63.50 | -660.50 | NA |
Fiscal Year end for NexImmune, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 3.51 | 2.75 | 4.68 | 10.00 | 7.78 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.51 | -2.75 | -4.68 | -10.00 | -7.78 |
Non-Operating Income | 1.18 | -0.32 | 0.01 | 0.14 | 0.22 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.33 | -3.08 | -5.36 | -9.85 | -7.57 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.33 | -3.08 | -5.36 | -9.85 | -7.57 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.33 | -3.08 | -5.36 | -9.85 | -7.57 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.38 | 1.25 | 1.05 | 1.05 | 1.04 |
Diluted EPS Before Non-Recurring Items | -1.69 | -2.21 | -4.99 | -9.40 | -7.25 |
Diluted Net EPS (GAAP) | -1.69 | -2.46 | -4.92 | -9.40 | -7.25 |